Summit Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Summit Therapeutics Inc. (SMMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 2.67 million shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-11-07
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-09-30 was 1.95M shares, a 94.77% increase year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-06-30 was 687.24K shares, a 61.91% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-03-31 was 38.25K shares, a 96.10% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-12-31 was 313.15K shares, a 64.47% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 4.10M shares, a 103.54% increase from fiscal 2021.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 2.01M shares, a 46.91% decline from fiscal 2020.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 3.79M shares.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 1.43M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2023-09-30 | 1.95M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 2.63M shares derived: sum of 2 quarters · filed 2023-11-07 | 2.67M shares 10-Q · filed 2023-11-07 | 2.99M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 687.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 725.49K shares 10-Q · filed 2023-08-09 | 1.04M shares derived: sum of 3 quarters · filed 2023-08-09 | 2.04M shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 38.25K shares 10-Q · filed 2023-05-11 | 351.40K shares derived: sum of 2 quarters · filed 2023-05-11 | 1.35M shares derived: sum of 3 quarters · filed 2023-05-11 | 3.16M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 313.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 1.31M shares derived: sum of 2 quarters · filed 2023-03-09 | 3.12M shares derived: sum of 3 quarters · filed 2023-03-09 | 4.10M shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 999.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 2.80M shares derived: sum of 2 quarters · filed 2022-11-09 | 3.78M shares 10-Q · filed 2022-11-09 | 4.67M shares derived: sum of 4 quarters · filed 2022-12-21 |
| 2022-06-30 | 1.80M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 2.78M shares 10-Q · filed 2022-08-11 | 3.67M shares derived: sum of 3 quarters · filed 2022-12-21 | 4.15M shares derived: sum of 4 quarters · filed 2022-12-21 |
| 2022-03-31 | 979.87K shares 10-Q · filed 2022-05-11 | 1.86M shares derived: sum of 2 quarters · filed 2022-12-21 | 2.34M shares derived: sum of 3 quarters · filed 2022-12-21 | 2.98M shares derived: sum of 4 quarters · filed 2022-12-21 |
| 2021-12-31 | 881.33K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | 1.36M shares derived: sum of 2 quarters · filed 2022-12-21 | 2.00M shares derived: sum of 3 quarters · filed 2022-12-21 | 2.01M shares 10-K/A · filed 2022-12-21 |
| 2021-09-30 | 482.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 1.12M shares derived: sum of 2 quarters · filed 2021-11-15 | 1.13M shares 10-Q · filed 2021-11-15 | |
| 2021-06-30 | 637.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 649.38K shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 11.98K shares 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 3.79M shares 10-K · filed 2021-03-31 | |||
| 2019-01-31 | 1.43M shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |